FLT3+ DC inhibits immune rejection via interaction with Treg in liver transplantation
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112289 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Jin-Ming Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Clinical Research Center for Pediatric Liver T…. Hauptthemen laut MEDLINE: Liver Transplantation, T-Lymphocytes, Regulatory, Dendritic Cells, fms-Like Tyrosine Kinase 3. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase (RTK) primarily expressed in hematopoietic stem cells and dendritic cells (DCs). While FLT3 plays a critical role in the proliferation, development and maintenance of DCs, thus influencing immune responses under both normal and pathological conditions, there also exists some evidence that FLT3+DC may be involved with immune responses in liver transplantation (LT). In this study, results from single-cell sequencing data analysis revealed a clear relationship between FLT3+DCs and Regulatory T cells (Tregs) in liver tissue of LT recipients. In peripheral blood samples of LT patients, levels of FLT3+DCs were decreased post-LT-surgery, while Tregs were increased. In a LT mouse model, levels of FLT3+DCs in the liver and bone marrow exhibited an initial time-dependent decrease followed by an increase after LT surgery. Results as obtained with co-culture experiments using mature BMDCs and CD4+ T cells revealed fluctuations in Tregs in response to FLT3 inhibitors and the FLT3 ligand. These findings suggest that FLT3+DCs could emerge as a novel target for mitigating immune rejection in LT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Clinical Research Center for Pediatric Liver Transplantation of Capital Medical University, Beijing, China; National…
- Organ Transplantation Center, Affiliated Hospital of Qingdao University, Qingdao, China.
- Department of Hepatopancreaticobiliary Surgery, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou 450003, China.
- Baylor College of Medicine, Houston, TX, USA.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J. M., Huang, H., Li, X. Q., Li, S. P., Zhou, L. X., Song, S. Y., & Zhu, Z. J. (2024). FLT3+ DC inhibits immune rejection via interaction with Treg in liver transplantation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112289
Vancouver
Zhang JM, Huang H, Li XQ, Li SP, Zhou LX, Song SY, et al. FLT3+ DC inhibits immune rejection via interaction with Treg in liver transplantation. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112289
BibTeX
@article{Zhang2024,
author = {Zhang, Jin-Ming and Huang, Hao and Li, Xin-Qiang and Li, Shi-Peng and Zhou, Liu-Xin and Song, Si-Yuan and Zhu, Zhi-Jun},
title = {FLT3+ DC inhibits immune rejection via interaction with Treg in liver transplantation},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112289}
}
EUVIMED